| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical |
Blood Purification Center, Beijing Chaoyang Hospital, Capital University of Medical Sciences, Beijing, China
Correspondence to: S.X. Wang, Blood Purification Center, Beijing Chaoyang Hospital, Capital University of Medical Sciences, 100020, Beijing, China. lihandp{at}yahoo.com.cn
Objective: To explore the safety and efficacy of
intravenous (IV) iron sucrose in maintenance peritoneal dialysis (PD). Design: Randomized, controlled, parallel-group
single-center trial. Setting: Blood Purification Center of Chaoyang, Beijing
Capital University of Medical Science, China. Methods: 46 patients on PD were involved in this trial.
26 patients received IV iron sucrose (200 mg iron) once per week for 4 weeks
then once every other week for a further 4 weeks. The other 20 patients
received oral ferrous succinate, 200 mg three times per day, for 8 weeks.
Hemoglobin, hematocrit, serum ferritin (SF) level, and transferrin saturation
(TSAT) were assessed at baseline and then again after 2, 4, and 8 weeks of
treatment. Results: There were no differences between the IV and
oral groups in terms of sex, age, duration of PD, mean dialysate dosage per
day, erythropoietin dosage per week, or hematological parameters at baseline.
After 4 and 8 weeks of treatment, mean Hb and Hct were significantly increased
in the IV group and were also significantly higher than those in the oral
group. Levels of SF and TSAT were also significantly increased in the IV
group, and significantly higher than in the oral group. After 8 weeks, the
response rate in the IV group was 94.8%, which was significantly higher than
that in the oral group. The mean erythropoietin dose was significantly lower
in the IV group than in the oral group. Hb, Hct, SF, and TSAT levels were
maintained between 4 and 8 weeks in the IV group despite the decrease in dose
frequency. There were no adverse events with IV iron. Eight patients in the
oral group had adverse gastrointestinal effects. Conclusion: IV iron sucrose is safe in PD patients. It
increases Hb levels and serum iron parameters more effectively than oral iron;
it is well tolerated and can permit reductions in the required dose of
erythropoietin.
KEY WORDS: Renal anemia; iron; erythropoietin (EPO); iron sucrose.
Received 11 June 2007; accepted 7 November 2007.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
 |
